SWOG clinical trial number
SWOG-9229

Concurrent Cisplatin, Prolonged Oral Etoposide and Vincristine Plus Chest and Brain Irradiation for Limited Small Cell Lung Carcinoma, Phase II Pilot

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Concurrent Cisplatin, Prolonged Oral Etoposide and Vincristine Plus Chest and Brain Irradiation for Limited Small Cell Lung Carcinoma, Phase II Pilot
Activated
02/15/1993
Closed
05/01/1994

Research committees

Lung Cancer

Publication Information Expand/Collapse

1998

Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229).

CR Thomas Jr;DJ Giroux;KJ Stelzer;JB Craig;LR Laufman;SA Taylor;JW Goodwin;JJ Crowley;RB Livingtson Int J Radiat Oncol Biol Phys 40(5):1039-1047

1995

Concurrent cisplatin (CDDP), prolonged oral etoposide (E) and vincristine (VCR) plus chest and brain irradiation (RT) induction therapy for limited-stage small cell lung carcinoma (SCLC): Preliminary report of a Southwest Oncology Group study (SWOG-9229)

CR Thomas Jr;DJ Rector;KJ Stelzer;RB Livingston ASCO 14:363(#1111)

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase